The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .
An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders.
OBJECTIVES This study aim ed to investigate the efficacy and tolerability of aripiprazole , an atypical antipsychotic with dual agonist and antagonist actions toward dopaminergic imbalance and partial serotonin-2A receptor antagonism , for treating children and adolescents with tic disorders . METHOD Twenty-four out patients aged 7 to 18 years with DSM-IV-diagnosed tic disorders were treated with aripiprazole using an open-label , flexible dosing schedule for 8 weeks from January 2005 to August 2006 . The Korean versions of the Yale Global Tic Severity Scale ( YGTSS ) , the Clinical Global Impressions-Improvement scale ( CGI-I ) , and the CGI-Severity of Illness scale ( CGI-S ) scores were used to measure the drug efficacy . Side effects were assessed using an adverse effect checklist , the Extrapyramidal Symptom Rating Scale , height and weight measurements , laboratory tests , and electrocardiograms . RESULTS Aripiprazole was prematurely discontinued in 6 ( 25 % ) of the 24 subjects due to intolerable adverse effects . After a mean of 9.8 + /- 4.8 mg/day of aripiprazole for 8 weeks , there was a 52.8 % reduction in the mean YGTSS Total Tic scores ( from 26.7 + /- 5.5 to 12.6 + /- 7.6 , p < .001 ) . Nineteen patients ( 79.2 % ) showed either much improved or very much improved status according to the CGI-I. The CGI-S score was also reduced ( from 5.5 + /- 0.5 to 3.0 + /- 1.4 , p < .001 ) . The initial dose of 5 mg/day aripiprazole for 2 weeks was also found to reduce tic symptoms significantly ( Total Tic scores decreased from 26.7 + /- 5.5 to 17.9 + /- 8.7 , p < .001 ) . Fourteen subjects ( 58.3 % ) experienced unwanted side effects , the most common being hypersomnia ( 37.5 % ) , nausea ( 20.8 % ) , and headache ( 16.6 % ) . CONCLUSION This open-label study suggests that aripiprazole is an efficacious and safe treatment for children and adolescents with tic disorders
The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .